Allon Therapeutics Wins National Biotech Award
Allon Therapeutics Inc. announced it will receive the Gold Leaf Award as the Early Stage Company of the Year (Health) from BIOTECanada, Canada’s national biotechnology industry organization. The award will be presented on June 28 at 4PM at the BIO 2011 International Convention in Washington, D.C.
BIOTECanada said Allon was chosen as the top pre-commercialization company in the Canadian biotechnology healthcare sector “by distinguishing themselves from their peers with demonstrated technology innovation and achieved milestones.”
Gordon McCauley, Allon’s President and CEO, said the prestigious Gold Leaf Award recognizes the Company’s clinical trial successes and progress toward commercializing products in devastating degenerative brain diseases, such as Alzheimer’s, Parkinson’s and several types of frontotemporal dementia.
“Being chosen as Canada’s leading pre-commercial healthcare biotech company is a great honour and an enormous compliment to the dedication, innovation, and excellence demonstrated by our team every day,” said McCauley. “It is also important recognition of the investigators, patients, and caregivers we partner with to find solutions to these awful diseases.”
Other news from the department business & finance
